Printer Friendly

FORTICAL NASAL SPRAY FOR OSTEOPOROSIS LAUNCHED.

Upsher-Smith Laboratories, Inc. Minneapolis, has launched new Fortical(R) calcitonin-salmon (rDNA origin) Nasal Spray, an effective treatment option for postmenopausal osteoporosis in women greater than 5 years postmenopause with low bone mass relative to healthy premenopausal women. Upsher-Smith commercializes the product today with shipments to the retail and wholesale trade, and will begin aggressively promoting to physicians through sales force detailing, national conventions, professional advertising and other promotion. Fortical(R) was developed, and will be manufactured for Upsher-Smith by Unigene Laboratories, Inc. (OTCBB: UGNE).

"Fortical(R) presents an exciting new option for women with postmenopausal osteoporosis," said Phill Dritsas, vice president, Marketing and Sales for Upsher-Smith. "Fortical(R) represents a pharmaceutically equivalent nasal calcitonin-salmon that provides a significant cost savings compared to the existing therapy. Further, Fortical(R) allows Upsher-Smith the opportunity to capitalize on our unique ability to offer an economical alternative and support physicians, retailers and managed care. Fortical(R) will conveniently fit into a woman's normal routine and can be taken before, during, or even after meals. The convenience of Fortical(R) may be just what many patients need to help diminish progressive osteoporotic bone loss."

New Fortical(R) Nasal Spray contains the active ingredient calcitonin-salmon. Calcitonin-salmon has been proven to produce statistically significant increases in lumbar vertebral bone mineral density (BMD) at just 6 months compared to placebo, with persistence at this level for up to 2 years of observation. Calcitonin-salmon has also been shown to increase hip BMD, at 12 months compared to placebo. Mark Evenstad, vice chairman and president, reflects on the company's pledge to market effective products to meet the ever-changing needs of both physicians and patients. "We continually strive to ensure the highest quality of our products. Fortical(R) is manufactured with a unique, patented recombinant DNA technology and safely treats postmenopausal osteoporosis with no reported serious drug-related gastrointestinal or esophageal adverse events."

"We are impressed that Upsher-Smith has launched Fortical(R) so rapidly following FDA approval," commented Dr. Warren P. Levy, president and CEO of Unigene. "Upsher-Smith's commitment to Fortical(R) is clear and we are enthusiastic about the product's commercial prospects."

New Fortical(R) Nasal Spray is available now, with a prescription, and is recommended in conjunction with adequate intake of calcium and vitamin D. Periodic nasal examinations are recommended; if nasal ulceration occurs, discontinue treatment until healed. Because calcitonin-salmon is a protein, the possibility of systemic allergic reaction exists. For more information and complete product information/most common adverse events for Fortical(R) Nasal Spray, visit http://www.upsher-smith.com or call 800/654-2299.

About Upsher-Smith:

Upsher-Smith Laboratories, Inc. is a fully integrated pharmaceutical company that manufactures and markets prescription pharmaceutical, OTC and cosmetic products. Upsher-Smith is also actively involved in licensing innovative compounds that are in clinical development.

About Unigene:

Unigene Laboratories, Inc. is a biopharmaceutical company focusing on the oral and nasal delivery of large-market peptide drugs. Due to the size of the worldwide osteoporosis market, Unigene is targeting its initial efforts on developing calcitonin and PTH-based therapies. Unigene has licensed worldwide rights for its oral PTH technology to GlaxoSmithKline. Unigene's patented oral delivery technology has successfully delivered, in preclinical and/or clinical trials, various peptides including calcitonin, PTH and insulin. Unigene's patented manufacturing technology is designed to cost-effectively produce peptides in quantities sufficient to support their worldwide commercialization as oral or nasal therapeutics.

For more information about Unigene, call 973/882-0860 or visit http://www.unigene.com.
COPYRIGHT 2005 Worldwide Videotex
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Biotech Business
Geographic Code:1USA
Date:Oct 1, 2005
Words:571
Previous Article:EXELIXIS INITIATES PHASE I CLINICAL TRIAL FOR ANTICANCER XL820.
Next Article:ARIAD GETS ORPHAN DRUG DESIGNATION FOR AP23573.
Topics:


Related Articles
NASTECH'S NASAL SPRAY BIOEQUIVALENT TO NASCOBAL NASAL GEL.
Nastech acquires Cedars-Sinai Medical Center patent estate for treatment of obesity.
Nastech acquires Cedars-Sinai Medical Center patent estate for treatment of obesity.
UNIGENE REPORTS RECORD REVENUE FOR 3RD QTR.
NASTECH COMPLETES FDA PAI FOR CALCITONIN-SALMON MANUFACTURE.
NASTECH'S NASAL SPRAY ALTERNATIVE TO APPROVED INJECTED PRODUCT.
When, how, and which one? Navigating the maze of osteoporosis drugs.
Nastech announces issuance of patents for parathyroid hormone nasal spray for osteoporosis.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters